Corcept Therapeutics Incorporated (CORT) Gains on FDA Approval, But Questions Remain

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the 5 Best Stocks to Buy for Short Term. On March 25, Wolfe Research upgraded Corcept Therapeutics Incorporated (NASDAQ:CORT) to Peerperform from Underperform following the FDA approval for relacorilant. The firm believes this approval will remove a major downside risk for the stock, adding that the sustainability of the company’s core Cushing’s syndrome franchise remains unclear.

On the same day, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced that the U.S. Food and Drug Administration approved Lifyorli (relacorilant) in combination with nab-paclitaxel as a solution for patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. This drug marks the first FDA-approved selective glucocorticoid receptor antagonist.

The trial achieved its dual primary endpoints, with patients treated with Lifyorli plus nab-paclitaxel witnessing a 35% reduction in the risk of death relative to patients treated with nab-paclitaxel alone. Additionally, patients saw a 30% lower risk of disease progression.

Overall, Corcept Therapeutics Incorporated (NASDAQ:CORT) has a Buy rating from 71% of the analysts covering the stock, with the remaining 29% holding a cautious view. The 1-year median price target of $60 reflects an upside potential of 59.19%.

Corcept Therapeutics Incorporated (NASDAQ:CORT), incorporated in 1998, is a California-based biopharmaceutical company that discovers and develops solutions for serious endocrinologic, oncologic, metabolic, and neurologic disorders.

While we acknowledge the risk and potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CORT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.